Here is the link to the "Cover Story" series of articles in the June 12 edition of Business Week on "The Genome Gold Rush", two of which refer to EXEL (although one article spells it incorrectly). If you try to link after the June 12 edition has been replaced by a later edition, Go to the indicated Business Week site and then follow links to the June 12 on-line edition. http://www.businessweek.com/contents.htm
Yes, this stock is hot. Yes, there is a lot of potential. Yes, $233 is not unrealistic - at some point.
Look at the drug companies that have joint working agreements and that have invested mega dollars in this company and it all makes sense. Look at the people. Look at the scientific writings and what others are saying.
The science has a ways to go, so it's a crapshoot. It's probably a crapshoot where the potential for significant gains far outweighs the risk of loss, when weighed on the basis of expected return compared to expected loss. But it could be years before we know.
Is this stock an essential part of a long term diversified portfolio? Absolutely. And only a fool would sell at 29 (or 39 or 89).
Should this stock be in my grandmother's portfolio? Not unless she is really reckless!
I was in at the start ($13) and I expect to be here for a long ride.
Any pending news? Nah! There was probably an information leak about efficiencies in employee benefits, controls for accounts payable or physical fitness of key employees.